Firstkind Ltd - geko® device’s Post

Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2

The 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) is an interesting read, this guide incorporates the latest clinical research, including The geko® device which significantly improves healing rates and patient outcomes. If you would like to learn more about The geko® device please do get in touch.

Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2

We are repeating our #BioMondeLIVE webinar on the Cost-Effectiveness of Debridement, today at 2pm 🕑 There is still time to register by completing this form 👉🏻 https://loom.ly/zldXuQ0 We will be analysing how cost effective various methods of wound debridement are, including a detailed focus on #LarvalTherapy. This information will aid your decision making when it comes to treatment pathway planning, and will provide advice on how to align those decisions to your clinical budgeting. #BioMonde #LarvalTherapy #WoundCare #Debridement

TWO2 is proven to outperform Standard of Care alone six-fold while also providing far more durable wound healing, but how does it compare against other advanced modalities? In our Real-World Evidence DFU study, the group receiving only TWO2 therapy, when compared to those receiving CTP, NPWT or GF, demonstrated significant reductions in both hospitalizations (6.9% vs 58.8%, p<0.0001) and amputations (13.8% vs. 35.3%, p = 0.016) over 12 months. This peer reviewed evidence suggests that TWO2 confers significant benefits over other adjunctive therapy options. These findings help to demonstrate the real-world, patient-centric value of TWO2 as both an adjunctive therapy and more effective alternative to other advanced wound care modalities. To read the study, visit https://lnkd.in/giCHkSw8. #TWO2heals #aotinc

Whether it's cystic fibrosis or ulcerative colitis, we understand the unique nuances of internal medicine trials. Recognizing the need for customized strategies across subspecialties, our team of therapeutically aligned experts take a tailored approach to navigating the complexities of your clinical trial – developing and implementing optimal clinical strategies, and maximizing patient impact. Learn more. https://bit.ly/3Xg3AbX #medicinetrials #clinicaltrials #patientimpact

🔍 Another great presentation highlighting the exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/e_CcmDX8 #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024

▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN  #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData 

Our informational symposium at #ASPN2024 starts at noon tomorrow and will emphasize the evidence behind Prospera™: ➡️ Learn about a robust clinical program that dates back to 2017 and includes multiple studies supporting therapy development, therapy validation, and a real-world study that validates the need for patient support beyond the implant. ➡️ Hear how proactive care is positively impacting patients, as demonstrated by real-world results from clinical practice. Don’t miss this opportunity to register: https://ow.ly/yf9M50Sv2Uu #BIOTRONIKNeuro #SpinalCordStimulation

🔍 Dive into clinical insights! New study reveals how standardisation in clinical trial design can enhance the validity of trial data for diabetic foot ulcers. 📊 Discover the key findings and implications for future research in wound care. Download a PDF copy: https://bit.ly/4cb0Kvl #ClinicalResearch #DiabeticFootUlcers #WoundHealing #ClinicalTrials #DFU #NATROXO2